SecBot SecBot
SC 13G ·Filed Nov 13, 2026

MTRI

InMed Pharmaceuticals Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed3d 10h ago SEC0001831942-26-000046
Passive investor 5%+ stake
Actionable Insight • Neutral

Monitor for any future amendments that could signal a shift from passive to active intent, particularly if Commodore Capital engages with management or increases its stake significantly. The combined passive ownership by Commodore, ADAR1 Capital (17.2%), and Ikarian Capital creates a notable institutional base post-merger.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Commodore Capital LP filed a Schedule 13G disclosing a 5.6% passive stake in Mentari Therapeutics (formerly InMed Pharmaceuticals), representing 2,977,630 common shares as of November 6, 2026. This is a new position following the company's reverse merger with Mentari on November 6, 2026, and adds to existing passive ownership by ADAR1 Capital (17.2%) and Ikarian Capital.

Key Financial Metrics

Stake
5.6%
Stake Value
$504.0K
Investor
Commodore Capital LP
Investor Type
hedge fund

Key Facts

  • Commodore Capital LP disclosed a 5.6% passive stake in Mentari Therapeutics (formerly InMed Pharmaceuticals) as of November 6, 2026.
  • The stake consists of 2,977,630 common shares, held via Commodore Capital Master LP.
  • The filing certifies passive intent under Rule 13d-1(c), with no intent to influence control.
  • Ownership percentage is based on 52,813,914 shares outstanding as of November 6, 2026, per the company's 8-K filed November 10, 2026.
  • This is a new position following the reverse merger with Mentari Therapeutics completed on November 6, 2026.

Financial Impact

5.6% stake valued at approximately $504,000 based on $9M market cap.

ownership concentration

Risk Factors

  • Passive stake filing; no indication of activist intent or engagement.
  • Small market cap ($9M) and low liquidity could amplify any future stake changes.
  • Post-merger company (Mentari Therapeutics) has limited public trading history.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G Filing (Primary)0001831942-26-000046
Document: 0001831942-26-000046-index-headers.html0001831942-26-000046
Document: 0001831942-26-000046-index.html0001831942-26-000046
Document: 0001831942-26-000046.txt0001831942-26-000046

US Market Status

Market Closed · Opens in 5h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026